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Purpose: A genetic component of osteoarthritis (OA) has been
established from family and twin studies with heritability esti-
mates of 42% to 60%. It is likely that multiple genes will be
involved, although the exact genes and their role have yet to be
elucidated. Published studies have examined over 80 genes for
their association with OA, however, of the positive associations
reported few have been replicated in independent cohorts. The
aim of this work was to attempt the replication of 12 published
genes (14 SNPs) shown to have signiﬁcant genetic association
with OA using a new case-control study of large joint OA.
Methods: An age- and gender-matched, case-control study was
undertaken in Nottingham, UK. Hospital-referred index cases
with symptomatic radiographic OA of the knee (F=506, M=536) or
hip (F=508, M=498) and asymptomatic controls (F=521, M=601)
were recruited. The replication tests undertaken are listed below.
Details of the gene, polymorphism associated in the literature
and the patient subset analyzed are included. In table a marker
of rs17561 (IL1A+4945), r2=1; bmarker of 86bp VNTR, r2=0.99
and cmarker of rs1800795 (IL6-174), r2=0.98. * kOA=knee OA;
hOA=hip OA; khOA=knee and hip OA; C=controls; F=females
Gene Polymorphism Phenotype*
IL1A ars1800587 (IL1A-889) kOA vs C
IL1B rs16944 (IL1B-511) hOA vs C
IL1B rs1143634 (IL1B+3954) hOA vs C
IL1RN brs419598 (IL1RN+8006) hOA vs C
IL6 crs1800797 (IL6-572) khOA vs C
IL4R rs1805013 (Ser11Leu) hOA vs C (F)
IL4R rs1805016 (Ser727Ala) hOA vs C (F)
COL2A1 rs2276455 (HindIII; 58330) 3+joints affected vs <3 joints affected
VDR rs731236 (Taq1) kOA vs C (F)
ESR1 rs2228480 (BtgI) kOA vs C
TGFB1 rs1982073 (Leu10Pro) khOA/kOA/hOA vs C (F)
ASPN rs5899161 (Asn repeat) khOA/kOA/hOA vs C
IGF1 rs10665874 (Promoter repeat) khOA/kOA/hOA vs C
ADAM12 rs3740199 (Gly48Arg) kOA vs C (F)
Additional SNPs (11) were genotyped across the TGFB1 gene,
giving an average SNP density of 1 every 2672 bp. Statistical
analysis compared the allele or genotype frequency of these
polymorphisms in the controls versus both knee and hip OA,
knee OA only and hip OA only. The analysis was adjusted (adj)
for age, gender and BMI. All genotyping was carried out using
ABI’s Taqman allelic discrimination assays except for the ASPN
and IGF1 repeats which were genotyped using ﬂuorescent PCR
followed by separation on an ABI 3730 DNA analyser.
Results: We were unable to conﬁrm the association with OA
for any of the 14 published SNPs. The TGFB1 SNP did show
some evidence of association with female hip OA (p=0.03).
However, our result differs from the published data, in that the
CC genotype was associated with increased risk and prevalence
of female spinal OA, while we found the CT genotype to be at
increased risk in female hip OA. In case this non-replication was
due to differences in population and phenotype, we genotyped
a further 11 SNPs across the gene. One SNP in the 5’ region
(rs4803457) showed some evidence for association with hip
OA (adj p=0.05). Another SNP located in the intronic region
(rs2278422) showed evidence of association with knee OA (adj
p=0.001) although this ﬁnding requires a cautious interpretation
as the genotype distribution in the controls was not in Hardy-
Weinberg equilibrium.
Conclusions: We were unable to replicate any of the published
genetic associations we investigated. Lack of replication is a
common occurrence and could be due to differences in study
design, phenotype or populations examined or the occurrence
of false positives in the initial study. Upon further analysis of the
TGFB1 gene we did detect weak evidence of association with
OA. This suggests that variants within the gene could have a
role in OA susceptibility. This new observation is of note as this
gene has been postulated to play a role in bone and cartilage
remodelling. However, replication and characterisation of this
exploratory ﬁnding in an independent study would be required
to understand if this was a chance ﬁnding or indeed if variation
within the TGFB1 gene contributes functionally to the disease
process in OA.
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Purpose: Transcriptomics has been used to analyze gene ex-
pression in tissues for target identiﬁcation and validation, how-
ever its application to the clinical end of drug discovery has been
more limited. The aims of this work were to: evaluate a method
for isolating RNA from samples collected directly in the clinic;
determine whether blood gene expression changes could detect
subtle distinctions between OA subsets; and evaluate a range of
clinical parameters as potential covariates.
Methods: Hospital-referred index cases with symptomatic radio-
graphic OA of the knee (kOA, n=103) or hip (hOA, n=103) and
asymptomatic controls (C, n=113), were recruited from a larger
case control study of large joint OA (the GOAL cohort) under-
taken in Nottingham, UK. Generalised OA (gOA) was deﬁned as
Heberden’s and/or Bouchard’s nodes affecting at least 2 ﬁngers
of each hand, plus knee OA. RNA was isolated from whole
blood, using the PAXgene™ collection tubes and RNA Kit (Pre-
Analytix). RNA from 36 females, age and BMI matched, (9 hOA,
7 gOA, 10 kOA, 10 C) was proﬁled using Affymetrix GeneChip
Human Genome U133 Plus 2.0 Arrays. Following quality con-
trol (QC) checks, principal component analysis (PCA) identiﬁed
covariates within the data set, which were incorporated into
ANOVA models to detect gene expression differences between
the subject groups. Selected genes were further proﬁled from
the same donors by quantitative PCR analysis, using TaqMan®
Low Density Arrays. Subsequently, these genes were proﬁled in
a different female cohort of 19 OA and control subjects.
Results: RNA was found to be of acceptable quality and quan-
tity for transcriptomic analysis. QC analysis of the Affymetrix
data highlighted distinct differences between the experimental
batches. Clinical parameters were investigated to identify co-
variates and highlighted the inﬂuence of hormone replacement
therapy on the gene expression data, which was then factored
into the statistical models. Thirty-nine genes from the Affymetrix
data were selected for quantitative PCR analysis using RNA
from the same donors based on P<0.05, false discovery rate
<40% and fold changes>1.3 if up- and >1.5 if down-regulated,
